Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
Genotype-Phenotype Correlation for DFNA22: Characterization of Non-Syndromic, Autosomal Dominant, Progressive Sensorineural Hearing Loss due to MYO6 Mutations
Audiology & Neuro-Otology, 11/05/09
Topsakal V et al. – This study describes the phenotype of 2 Belgian families with SNHL linked to DFNA22, both with a pathogenic change in the deafness gene MYO6. The phenotypes of all hitherto reported DFNA22 families with mutations in the MYO6 gene have been studied and compared. It seems that genetic defects that spare the motor domain of the myosin VI protein have a milder phenotype.
Related Articles
Additional heterozygous 2507A>C mutation of WFS1 in progressive hearing loss at lower frequencies
The Laryngoscope, 11/05/09
Relevance Score: 68%
High incidence of hearing loss in long-term survivors of multisystem langerhans cell histiocytosis
Pediatric Blood & Cancer, 10/22/09
Relevance Score: 68%
Acoustic analysis of voice in cochlear implant recipients with post-meningitic hearing loss
Cochlear Implants International, 10/07/09
Relevance Score: 68%
Acute-Onset Unilateral Psychogenic Hearing Loss in Adults: Report of Six Cases and Diagnostic Pitfalls
Journal for Oto-Rhino-Laryngology, 10/23/09
Relevance Score: 67%
Diagnosing hearing problems
Paediatrics and Child Health, 10/06/09
Relevance Score: 67%
Today in ENT...keeping you current
Receive free subspecialty "5-minute updates" via email
Early Prediction of Response to Chemoradiotherapy for Head and Neck Cancer
Archives of Otolaryngology, 11/25/09
N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09
Laser-induced thermal therapy and cisplatin for recurrent head and neck cancer: A case characterized by an unusually long disease-free survival
ENT Journal, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


